Patients receiving educational or behavioral interventions aimed at controlling hyperphosphatemia had an average reduction in phosphate of 0.23 mmol/L more than standard care patients.
Converting hemodialysis patient to sucroferric oxyhydroxide from a previous binder increased the proportion of patients achieving target serum phosphorus levels.
Survival improved by 12% when serum phosphate levels approached a safer target range.
In a study of hemodialysis patients, mortality risk increased along with phosphorus level, particularly among patients with higher residual renal urea clearance.
At 18 months, PTH levels were within target for 67% and 68% of participants who initiated etelcalcetide at 2.5 mg and 5 mg, respectively.
Nearly twice as many patients achieved the target phosphorus range after a year of taking the phosphate binder, regardless of iPTH level.
Replacing foods containing phosphorus-based additives with similar foods not containing these additives can control hyperphospatemia without interfering with nutritional status.
Alkaline phosphatase was more strongly linked to mortality compared with other biomarkers of chronic kidney disease-mineral and bone disorder.
In a study, 25.8% and 37.8% of calcium acetate and calcium carbonate users, respectively, exceeded the maximum recommended daily intake.
In a study 52.1% of patients receiving ferric citrate attained a 1.0 g/dL or greater increase in hemoglobin compared with just 19.1% receiving placebo.
Purgative products introduce 10 times the normal daily amount of phosphorus into the body.
Younger patients are less likely to respond to treatment with sucroferric oxyhydroxide or sevelamer.
Study implicates amlodipine, lisinopril, clonidine, acetaminophen, and omeprazole.
The percentage of patients with serum phosphorus levels of 5.5 mg/dL and below more than doubled to 37.8% after 6 months of treatment with sucroferric oxyhydroxide.
Patients also needed fewer phosphate binder pills over time.
The risk of end-stage renal disease was 83% higher for those who drank more than 7 glasses of diet soft drinks weekly.
It can sharply lower serum phosphorus levels and reduce dependence on phosphate binders.
In a study, 69.7% of intervention patients attained serum phosphorus levels below 5.5 mg/dL, compared with just 18.5% of control patients.
A low protein, low phosphorus diet plays an important role in the nutritional management of patients transitioning to once-weekly incremental hemodialysis.
Hyperphosphatemia was associated with more than double the risk of death from any cause.
Patients reduced dietary phosphorus without compromising protein intake.
The USDA Standard Nutrient Reference Database, for example, listed phosphorus amounts for just 5 of 46 beverages.
For each 1 mmol/L increase in serum phosphorus, the odds of left ventricular hypertrophy more than doubled.
Calcium-based binders, however, are associated with greater odds of all-cause mortality versus sevelamer.
In a study, 61% of hemodialysis patients reported accidentally forgetting to take their medication or otherwise skipping doses unintentionally.
Over 33 months, the 25-hydroxyvitamin D level of ergocalciferol recipients increased significantly from 15.14 to 37.32 ng/mL.
Researchers evaluated the efficacy of 100 mg/day of niacin in hemodialysis patients.
The phosphate binder is a useful treatment for hyperphosphatemia with a relatively low pill burden, researchers say.
Patients may need no more than routine evaluation of iron.
Phosphorus targets in patients with chronic kidney disease stage 3 to 4 should be below 4.3 mg/dL, researchers report.
Renal and Urology News Articles
- Intensive Blood Pressure Reduction Benefits CKD Patients
- Study: Ureterolithotripsy Best for Large Proximal Ureteral Stones
- Reducing Serum Phosphorus to Safer Target Range Ups Survival
- Post-RP Radiotherapy Benefits Selected Men With Elevated PSA
- Switch to an Iron-Based Binder Found to Improve Phosphorus Lowering
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)